Podcast
Questions and Answers
What is the recommended pharmacological approach for people with mild to moderate Alzheimer's disease?
What is the recommended pharmacological approach for people with mild to moderate Alzheimer's disease?
- Memantine as a first-line treatment
- No pharmacological treatment is recommended
- Donepezil, galantamine, or rivastigmine as single agents (correct)
- Donepezil, galantamine, or rivastigmine in combination with memantine
When should memantine be considered for people with Alzheimer's disease?
When should memantine be considered for people with Alzheimer's disease?
- If they have mild disease and are not taking an AChE inhibitor
- If they have severe disease and are taking an AChE inhibitor
- If they have moderate disease and are intolerant or have a contraindication to an AChE inhibitor (correct)
- If they have any severity of disease and are not taking an AChE inhibitor
What is the recommended approach for people with dementia with Lewy bodies who are intolerant to AChE inhibitors?
What is the recommended approach for people with dementia with Lewy bodies who are intolerant to AChE inhibitors?
- Do not consider any pharmacological treatment
- Consider memantine as a first-line treatment
- Consider galantamine only if donepezil and rivastigmine are not tolerated (correct)
- Consider galantamine as a first-line treatment
What is the recommended approach for people with vascular dementia?
What is the recommended approach for people with vascular dementia?
What is the recommended approach for people with Alzheimer's disease who are already taking an AChE inhibitor and have severe disease?
What is the recommended approach for people with Alzheimer's disease who are already taking an AChE inhibitor and have severe disease?
What is the recommended pharmacological approach for people with mild to moderate dementia with Lewy bodies?
What is the recommended pharmacological approach for people with mild to moderate dementia with Lewy bodies?
What is the primary focus of the initial and ongoing management of non-cognitive symptoms in people living with dementia?
What is the primary focus of the initial and ongoing management of non-cognitive symptoms in people living with dementia?
In what circumstances can antipsychotics be offered to people living with dementia?
In what circumstances can antipsychotics be offered to people living with dementia?
What should be considered when discussing antipsychotics with the person and their family members or carers?
What should be considered when discussing antipsychotics with the person and their family members or carers?
What should be avoided in people living with dementia, due to the increased risk of stroke and death?
What should be avoided in people living with dementia, due to the increased risk of stroke and death?
What should be stopped if no clear ongoing benefit is seen, and after discussion with the person and their family members or carers?
What should be stopped if no clear ongoing benefit is seen, and after discussion with the person and their family members or carers?
What is not recommended for managing agitation or aggression in people living with dementia, unless indicated for another condition?
What is not recommended for managing agitation or aggression in people living with dementia, unless indicated for another condition?
